Pemvidutide: Two Liver Endpoints, Different Results
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

Pemvidutide research shows why a trial can have more than one important result. The IMPACT study assessed liver inflammation and scarring as distinct outcomes. This randomized phase two study enrolled 212 people with biopsy-confirmed MASH and moderate-to-advanced fibrosis. Its published analysis assessed two primary endpoints at 24 weeks. Pemvidutide met the endpoint of MASH resolution without worsening fibrosis. It did not meet the separate endpoint of fibrosis improvement without worsening MASH at that time. Both findings belong in the summary. Longer follow-up matters, and one favorable biopsy endpoint does not establish prevention of liver failure or overall long-term safety.

END CARD
Research explained. Not medical advice. Sources and limitations in the accompanying transcript.

SOURCES
[1] Noureddin et al. (2025): Safety and efficacy of pemvidutide versus placebo for MASH, IMPACT 24-week results
https://pubmed.ncbi.nlm.nih.gov/41237796/
Primary human randomized phase 2b trial

EVIDENCE LIMITATIONS
The script deliberately describes the published 24-week analysis, not every subsequent result.
Meeting one primary endpoint does not imply the other was met.
Biopsy endpoints are not equivalent to liver-related morbidity, survival, or lifelong safety.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
Pemvidutide: Two Liver Endpoints, Different Results